Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2021 Nov 10;16(11):e0257549. doi: 10.1371/journal.pone.0257549

Laminar flow ventilation system to prevent airborne infection during exercise in the COVID-19 crisis: A single-center observational study

Yoshinori Katsumata 1,2,*, Motoaki Sano 2, Hiroki Okawara 3, Tomonori Sawada 3, Daisuke Nakashima 3, Genki Ichihara 2, Keiichi Fukuda 2, Kazuki Sato 1, Eiji Kobayashi 4
Editor: Davor Plavec5
PMCID: PMC8580245  PMID: 34758032

Abstract

Particulate generation occurs during exercise-induced exhalation, and research on this topic is scarce. Moreover, infection-control measures are inadequately implemented to avoid particulate generation. A laminar airflow ventilation system (LFVS) was developed to remove respiratory droplets released during treadmill exercise. This study aimed to investigate the relationship between the number of aerosols during training on a treadmill and exercise intensity and to elucidate the effect of the LFVS on aerosol removal during anaerobic exercise. In this single-center observational study, the exercise tests were performed on a treadmill at Running Science Lab in Japan on 20 healthy subjects (age: 29±12 years, men: 80%). The subjects had a broad spectrum of aerobic capacities and fitness levels, including athletes, and had no comorbidities. All of them received no medication. The exercise intensity was increased by 1-km/h increments until the heart rate reached 85% of the expected maximum rate and then maintained for 10 min. The first 10 subjects were analyzed to examine whether exercise increased the concentration of airborne particulates in the exhaled air. For the remaining 10 subjects, the LFVS was activated during constant-load exercise to compare the number of respiratory droplets before and after LFVS use. During exercise, a steady amount of particulates before the lactate threshold (LT) was followed by a significant and gradual increase in respiratory droplets after the LT, particularly during anaerobic exercise. Furthermore, respiratory droplets ≥0.3 μm significantly decreased after using LFVS (2120800±759700 vs. 560 ± 170, p<0.001). The amount of respiratory droplets significantly increased after LT. The LFVS enabled a significant decrease in respiratory droplets during anaerobic exercise in healthy subjects. This study’s findings will aid in exercising safely during this pandemic.

Introduction

Human-to-human transmission of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mainly occurs through respiratory droplets emitted by asymptomatic infected individuals [1, 2]. After the end of the state of emergency and reopening of gyms, many individuals no longer felt comfortable going to the gym [3, 4]. In poorly ventilated and enclosed spaces, exercise-induced labored breathing can result in higher concentrations of virus-containing respiratory droplets from an infected person, thereby increasing the risk of airborne transmission if another individual shares or enters the same space soon after an infected person leaves [57]. However, literature on the extent of particulate generation during exercise-induced exhalation is scarce [8], and scientific infection-control measures are inadequately implemented. Therefore, it is urgent to apply an innovative system to prevent SARS-CoV-2 infection during exercise, especially indoor fitness activities.

The laminar airflow ventilation system (LFVS) combined with high-efficiency particulate absorbing (HEPA) filters is used in operating rooms and clean benches to remove moderate-to-large-sized fractions of aerosols from airstreams inside rooms [9, 10]. HEPA filters can remove at least 99.95% of particulates with diameters >0.3 μm. Therefore, the LFVS technology was used to develop a preventive measure against airborne infection among treadmill users during the coronavirus disease (COVID-19) crisis. This study aimed to investigate the relationship between the number of aerosols during training on a treadmill and exercise intensity and to elucidate the effectiveness of the LFVS in aerosol removal during anaerobic exercise.

Materials and methods

LFVS

A considerable amount of airflow would be required to make the entire room sterile. Therefore, the LFVS was developed as a booth to remove only the respiratory droplets in the exhalation area of runners (Figs 1 and 2). The booth has a frame structure with a height of 2140 mm, width of 1000 mm, and depth of 1560 mm, and it is separated from the surrounding area using a vinyl sheet. Air was emitted from the ceiling-mounted air supply unit above the treadmill (push) and drawn in the exhaust unit on the floor in front of the treadmill (pull; Figs 1 and 2) to maintain a constant vertical laminar flow from the ceiling to the treadmill’s running plate. Airflow and exhaust volume were optimized by verifying changes in the airflow from the humidifier. The airflow rate of the air supply unit is 12 m3/min, creating a laminar flow from the air-blowing surface to the exhaled area of the runner at a velocity of approximately 0.5 m/s. The exhaust unit has a treatment air volume of 16 m3/min. The treatment air volume of the exhaust unit is 16 m3/min. Thus, the LFVS facilitated vertical displacement of aerosolized droplets of various sizes sprayed horizontally from the runner’s mouth and nose during respiration. Moreover, HEPA filters were installed on both units to trap the virus (Fig 1).

Fig 1. Laminar airflow ventilation system comprising an air supply unit and an exhaust unit.

Fig 1

The air supply unit ensures high-efficiency particulate air (HEPA)-filtered vertical airflow from over the runner’s head, whereas the exhaust unit draws contaminated air into the treadmill board. A booth encloses all three sides except for the entrance to the treadmill to maintain the laminar flow. The air sanitized by the HEPA filter in the exhaust unit is vented outside the booth.

Fig 2. Performance of the laminar airflow ventilation system (LFVS) using artificial droplets.

Fig 2

(A and B) The airflow was observed using an airflow indicator tube located at a position assumed to be the breathing. (C–F) The four types of vertical airflow, including (C) not-activating the LFVS, D: activating only the exhaust unit (Exhaust ON), (E) activating only the air supply unit (Supply ON), (F) activating the two units (Supply and Exhaust ON).

Number of dust particulates sprayed from the ultrasonic humidifier

The performance of the LFVS was evaluated on a stand-alone unit without a treadmill in the absence of frontal disturbance, using artificial droplets. An ultrasonic humidifier was used to spray 1 L/h of steam from the discharge port (30 mm diameter) at a position assumed to be the breathing area, and the number of dust particulates was measured by a particulate counter (RION, Tokyo, Japan) at a distance 20 cm away from the blowout port. The particulate counter measured the number of particulates per cf (28.3 L) through a 1/100 diluter (TOPAS GmbH, Dresden Germany). Particulates (>0.3 μm) were measured every 1 minute, 10 times in an unloaded state with a humidifier, a loaded state with a humidifier, and a loaded state with a humidifier and the LFVS activated.

Air was emitted from the ceiling-mounted air supply unit above the treadmill and drawn in from the exhaust unit on the floor. Airflow and exhaust volume were optimized by visually verifying changes in the humidifier’s airflow. By constructing air filtration using the HEPA filter in the exhaust unit, this system enabled the capture of respiratory droplets containing SARS-CoV-2 emitted by asymptomatic infected individuals.

The airflow that formed in the booth

The airflow was visualized using an airflow indicator tube (no. 301, Komyo Rikagaku Kogyo K.K. Kanagawa, Japan) located at a position assumed to be the breathing area (Fig 2A and 2B and S1 Movie). The smoke diffusion pattern was captured in different states, including a non-activated LFVS (OFF), only the exhaust unit activated (Exhaust ON), only the air supply unit activated (Supply ON), and the LFVS activated (Supply and Exhaust ON). The smoke was stagnant owing to the updraft in an unloaded state with the airflow indicator tube (Fig 2C). Smoke was drawn in the exhaust unit while lingering inside the booth when activating only the exhaust unit (Fig 2D). Smoke diffusion was controlled, but some smoke leaked outside the booth, activating only the air supply unit (Fig 2E).

Study sample and ethical approval

Subjects aged 20–80 years were recruited via a web system in October 2020. Exclusion criteria included receiving medication and having comorbidities, such as hypertension, diabetes, or active lung diseases. Twenty healthy subjects enrolled in this study had a broad spectrum of aerobic capacities and fitness levels, including athletes. One of them had experienced a subdural hematoma 6 months ago. At the time he participated in this study, he was cured of his disease and was not receiving ongoing treatment. In addition, he was actively engaged in daily exercise. All of them received no medication. They can be considered representative of a larger population. The study protocol was approved by the Institutional Review Board (IRB) of Keio University School of Medicine [permission number; 20190229], and the study was conducted in accordance with the Declaration of Helsinki. Subjects provided verbal informed consent because the IRB approved use of oral consent in accordance with Japanese guidance for clinical research. Verbal consents were recorded as experimental notes in this study.

Experimental procedure

The exercise tests were performed on a treadmill at Running Science Lab in Japan, simultaneously monitoring particulates emitted by subjects with a particulate counter every minute. During exercise, the lactate concentration in sweat was monitored with a sweat lactate sensor attached to the upper arm (Graceimaging Inc., Tokyo, Japan) to determine the lactate threshold (LT), [11] and the heart rate was monitored using Duranta (Zaiken, Tokyo, Japan). The first 10 subjects were registered to examine whether exercise increases airborne particulate concentration in the exhaled air. The other 10 subjects were registered to investigate the effective removal of micro-droplets emitted during exhalation when running on the treadmill using the LFVS. The two groups exercised according to the same protocol, and the LFVS was activated during constant exercise for 4 minutes after reaching 85% of the expected maximum heart rate. Then, the exercise was continued for another 6 minutes, activating the LFVS.

Exercise testing protocol

On the day of the exercise test, the subjects avoided heavy physical activity before the test. The subjects performed the test in the upright position on a treadmill (Elevation Series®, Life Fitness, Illinois, USA). The subjects performed a 5-minute warm-up from 5 to 10 km/h with a 1-degree incline according to their conditions after a 2-minute rest to stabilize the heart rate and respiratory condition. Then, the exercise intensity was gradually increased by 1-km/h increments, followed by 10 minutes of constant-load exercise at 85% of the expected maximum heart rate (220 − age). For some subjects, the loading volume was fine-tuned to maintain the heart rate at 85%.

Particulates count in exercise

A particulate counter placed 10 cm away from the treadmill runner’s mouth measured the exhaled air’s droplet concentration. After being diluted 100-fold in a diluter, the number of particulates was analyzed using an instrument. The number of particulates was measured every minute from 2 minutes before starting the exercise through to the end.

LT in sweat

LT was defined as the first significant increase in the lactate concentration in sweat above the baseline based on the graphical plots [11]. Three researchers, independent of the researchers who analyzed respiratory gas exchange, jointly agreed on the point of LT.

Statistical analyses

The results are presented as means with standard deviations for continuous variables and as percentages for categorical variables, as appropriate. Based on a pre-performed Shapiro-wilk test, multiple comparisons of changes (Δ) in the number of airborne particulates involving each incremental exercise period from the warm-up were made using the repeated analysis of variance with the Dunnet test as a post-hoc test. Student’s paired t-test was used to compare the droplet concentrations from spray or from the oral cavity during vigorous exercise before and after the activation of LFVS. Cohen’s d was calculated using the value of t for paired t test. SPSS, version 25.0 (SPSS Inc., Chicago, Illinois), was used for analysis, and p<0.05 (2-sided) was set to define statistical significance.

Patient and public involvement

There was no active patient involvement in the design of the study or in the recruitment to, or conduct of, the study. The subjects participated in this study after receiving an explanation of the protocol approved by the Institutional Review Board of the Keio University School of Medicine.

Results

Non-clinical study of the LFVS

A constant vertical laminar flow was observed only when the LFVS was activated but not when the air supply unit or exhaust unit was activated (Fig 2F and S1 Movie). S1 Fig shows the response of the LFVS to emitting particulates from the ultrasonic humidifier. The particulates of >0.3 μm sprayed from ultrasonic humidifier were almost completely removed by the LFVS (3717040 ± 72347 vs. 60 ± 84; p < .001, n = 10) as well as particulates of sizes >0.5 μm (327780 ± 22908 vs. 0±0; p<0.001, n = 10) and >1.0 μm (23620 ± 2504 vs. 0±0; p<0.001, n = 10).

Monitoring particulates during exercise

Baseline characteristics of the subjects are summarized in Table 1. The subjects were predominantly male (80%), with an average age of 29 ± 12 years. Fig 3 shows the representative data for the particulates, lactate in sweat, and heart rate during exercise. A steady number of particulates before the LT was followed by a significant and gradual increase in the respiratory droplets after the LT, particularly during anaerobic exercise with a large effect size (Fig 3 and Table 2).

Table 1. Baseline characteristics of patients.

Characteristics Total Off On P-value
Age, years 29 ± 12 24 ± 6 34 ± 14 0.08
Male, n (%) 16 (80) 9 (90) 7 (70)
Height, cm 169 ± 8 171 ± 5 167 ± 9 0.30
Body weight, kg 60 ± 12 64 ± 13 56 ± 9 0.11
BMI, kg/m 2 20.8 ± 2.6 21.8 ± 3.1 19.8 ± 1.7 0.10
Exercise >3 times/week, n (%) 10 (50) 4 (40) 6 (60)
1–2 times/week, n (%) 6 (30) 3 (30) 3 (30)
Sedentary life, n (%) 4 (20) 3 (30) 1 (10)
Load at 85% of the EMHR, km/h 13 (3) 13 (3) 14 (4) 0.38

Abbreviations: BMI; body mass index, EMHR; expected maximum heart rate.

Fig 3. Airborne particulates generation during exercise.

Fig 3

(A) Representative graphs of the concentration of airborne particulates (<0.3 μm; red dots), sweat lactate (blue dots) levels, and heart rate (gray dots) during exercise. (B) Changes (Δ) from the warm-up in the number of airborne particulates (>0.3 μm; n = 10). #p<0.01, ##p<0.001 compared with the warm-up. LT, lactate threshold; 85%_1, the first half of the constant-load exercise at 85% of the expected maximum heart rate; 85%_2, the latter half of the constant-load exercise at 85% of the expected maximum heart rate.

Table 2. Airborne particulate generation during exercise.

rest Warm-up Pre-LT Post-LT 85%_1 85%_2
Mean difference ± SD (95%CI) 731.3 ± 760.0 (-2727.6–4190.2) - -27.5 ± 850.9 (-3591.9–3537.0) 1552.4 ± 1667.4 (-2012.0–5116.9) 4653.4 ± 3380.5 (1088.9–8217.8) 10727.3 ± 7060.6 (7162.8 ± 14291.7)
p-value# 0.97 - 1.00 0.64 < 0.01 < 0.001
Power 0.77 - 0.05 0.75 1.00 1.00

Repeated analysis of variance with Dunnet test as post-hoc test revealed a significant and gradual increase in the respiratory droplets with time.

#p value compared with the warm-up.

LT, lactate threshold; 85%_1, the first half of the constant-load exercise at 85% of the expected maximum heart rate; 85%_2, the latter half of the constant-load exercise at 85% of the expected maximum heart rate.

Effect of the LFVS on the particulates during vigorous exercise

The LFVS was activated during a constant load of exercise intensity above the LT, in which the concentration of particulates in the exhaled air increased. Notably, particulates exhaled during exercise were almost completely removed by the LFVS (>0.3 μm: 2120800±759700 vs. 560 ± 170; p<0.001, p<0.001, n = 10; Fig 4 and Table 3).

Fig 4. Airborne particulate generation during anaerobic exercise using the laminar airflow ventilation system (LFVS).

Fig 4

(A) Representative graphs of the concentration of airborne particulates (<0.3 μm) (red dots) in activating the LFVS during constant exercise 4 minutes after reaching 85% of the expected maximum heart rate. (B) Concentration of airborne particulates (>0.3 μm) before and after the activation of the LFVS (n = 10). ##p<0.001 compared with the off LFVS, 85%, constant-load exercise at 85% of the expected maximum heart rate, LT, lactate threshold.

Table 3. Airborne particulate generation during anaerobic exercise using the laminar airflow ventilation system (LFVS).

LFVS off LFVS on Difference p-value Cohen’s d Power
Mean (SD) 95%CI Point 95%CI
Number of particles 21208.2 (7596.9) 5.6 (1.7) 21202.7 (7596.9) 15768.2–26637.1 p < 0.01 p < 0.01 2.791 1.368–4.188 1.00

Mean (SD) was shown.

Abbreviation: LFVS, Laminar airflow ventilation system.

Discussion

The most striking result among our findings is that exercise below the LT did not increase the particulate concentration in the exhaled air. In contrast, higher-intensity anaerobic exercise continuation increased the exhaled droplet concentration. In addition, the LFVS enabled a significant decrease in particulates emitted from the oral cavity during vigorous exercise.

LFVS during treadmill exercise

Adequate regular physical activity is paramount to maintaining good health [1216]. Moreover, current clinical practice guidelines and expert statements recommend that adults should engage in at least 150 minutes of moderate-intensity aerobic physical activity, which consists of at least 75 minutes of vigorous-intensity aerobic physical exercise each week [17]. However, indoor exercise, such as in a training gym, had been banned during the state of emergency due to the COVID-19 pandemic in many countries [3]. Furthermore, decreased physical activity and associated worse depression, loneliness, stress have been observed [1821]. The virus can spread by close contact and indirect contact through contaminated objects [2, 22]. Indoor sports centers have been re-opened after the end of the state of emergency, and the infection has been controlled with hand washing, social distancing, and prohibiting high-intensity exercise [23]. Of respiratory droplets during exercise, droplets with a diameter of 10 μm or more fall to the ground immediately after traveling a distance of 1–2 m. However, smaller droplets (i.e., aerosols) are known to remain suspended in the air for hours [24, 25]. Recently, the virus has been found in small aerosols and has been shown to maintain viability in such aerosols for hours [5, 26]. Thus, it would be judicious to take precautionary measures to control airborne transmission of infection. Particularly, when using treadmill training installed in many gyms, preventing infection from droplets by simply securing social distancing or space partitioning is challenging. The use of efficient ventilation, high-efficiency air filters, and ultraviolet lamps is expected to overcome this problem. Based on the guidelines for the prevention of surgical site infection issued by the Centers for Disease Control and Prevention [9], a ventilation system (LFVS) to create a sterile vertical laminar flow was developed. A considerable amount of airflow would be required to make the entire room sterile. Therefore, the LFVS was developed as a booth to remove the respiratory droplets only in the exhalation area of runners (Fig 1). It was shown that pull alone through the exhaust or push alone from the supply unit was not effective in removing particulates. However, the LFVS effectively and completely prevented the diffusion of particulates into the room, even under high-intensity training conditions. With its inbuilt virus-removal mechanism (HEPA filters), this novel ventilation system creates a sterile vertical laminar flow and potentially inhibits cluster generation associated with airborne transmission in the gym.

Exercise during the COVID-19 crisis

Little is known about respiratory droplets during physical exercise [2729]. In this study, a sweat lactate sensor was used to examine in detail the relationship between the number of respiratory droplets from exhaled air and anaerobic threshold (Figs 3 and 4). As reported by Seki et al., non-invasive and continuous monitoring of sweat lactate values during exercise using a sweat lactate sensor has been shown to strongly correlate with ventilatory threshold assessed with exhaled gas analysis [11]. It was shown that the number of expiratory particulates increased in all cases when exercise was continued at 85% of the predicted maximum heart rate. In about half of the cases, the significant rise in aerosol occurred beyond the LT, suggesting that the aerosol elevation timing depends on the subject’s exercise style (e.g., breathing technique, muscle usage, etc.). Conversely, none of the patients had an aerosol elevation before LT. A high ventilation/perfusion mismatch is observed due to differences in blood flow and ventilation at rest. After the start of exercise, a mild increase in minute ventilation (VE) was comparable to the oxygen uptake (VO2) increase because of improved ventilation/perfusion mismatch [30]. After the LT, VE increased independently of VO2 because of a significant increase in CO2 consumption (VCO2), and the increased respiratory rate led to respiratory muscle fatigue [31]. Consequently, increased aerosol levels could be observed during exercise above the LT. Continuous exercise at 85% of the predicted maximum heart rate led to the persistent elevation of the respiratory droplets, following a sustainable increase in the VO2 because of fatigue and decreased exercise efficiency [32]. These findings suggested that aerobic exercise below the LT should be promoted even during the COVID-19 crisis to strengthen the immune system. Conversely, anaerobic exercise indoors should be carefully practiced with more robust infection-control measures.

New lifestyle during the COVID-19 crisis

The promotion of hand washing, and social distancing is the most effective for COVID-19 prevention. However, interpersonal communication is essential to maintain mental and physical well-being despite the fears of coronavirus transmission. The abovementioned system is useful for safely improving physical activity during the COVID-19 crisis [33]. Furthermore, this system could be adapted to places where face-to-face interaction is required.

Limitations

The present study has some limitations. First, as a single-center observational study, there may have been a selection bias. Second, our study did not allow for an examination of the possibility of LFVS in preventing the COVID-19 infection. A further randomized study with a large sample size and long-term follow-up for the prevention of COVID-19 infection is required to overcome these limitations.

Conclusion

Exercise before the LT showed no increase in respiratory droplets, but anaerobic exercise revealed a significant increase. LFVS enabled a significant decrease in respiratory droplets during anaerobic exercise in healthy subjects, which may be useful for safely improving physical activity during the COVID-19 crisis.

Supporting information

S1 Fig. Particulates from an ultrasonic humidifier using the laminar airflow ventilation system (LFVS).

Particulates from an ultrasonic humidifier using the laminar airflow ventilation system (LFVS). The concentration of particulates (>0.3 μm) from an ultrasonic humidifier before and after the activation of the LFVS (n = 10). ##p<0.001 compared with the off LFVS.

(PDF)

S1 Movie. The performance of the vertical laminar flow ventilation system using artificial droplets.

(AVI)

S1 File. Data set.

(XLSX)

Acknowledgments

The authors thank T. Iida, T. Yamada, and Y. Mita (who manage the Science Laboratory, Tokyo, Japan) for their technical assistance. We are grateful to Editage for editing this manuscript.

Abbreviations

COVID-19

coronavirus disease

HEPA

high-efficiency particulate absorbing

LFVS

laminar airflow ventilation system

LT

lactate threshold

SARS-CoV-2

severe acute respiratory syndrome coronavirus 2

VCO2

increase in CO2 consumption

VE

minute ventilation

VO2

oxygen uptake

Data Availability

All relevant data are within the manuscript and its Supporting information files.

Funding Statement

Nippon Medical & Chemical Instruments Co. Ltd. developed the laminar airflow ventilation system and provided support in the form of financial supports for authors YK and EK. This work was also partly supported by a Grant-in-Aid from Scientific Research from the Japan Agency for Medical Research and Development [ID. JP21ek0210130] and by Kimura Memorial Heart Foundation Research Grant for 2019 [N/A], Suzuken Memorial Foundation [N/A], Foundation for Total Health Promotion [N/A], and Research Grant for Public Health Science[N/A]. The did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.

References

  • 1.World Health Organization. Transmission of SARS-CoV-2: implications for infection prevention precautions: scientific brief. https://www.who.int/publications/i/item/modes-of-transmission-of-virus-causing-covid-19-implications-for-ipc-precaution-recommendations. Accessed 24 Jul 2020.
  • 2.Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382(13): 1199–1207. doi: 10.1056/NEJMoa2001316 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Blocken B, van Druenen T, van Hooff T, Verstappen PA, Marchal T, Marr LC. Can indoor sports centers be allowed to re-open during the COVID-19 pandemic based on a certificate of equivalence. Build Environ. 2020;180: 107022. doi: 10.1016/j.buildenv.2020.107022 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Chirico A, Lucidi F, Galli F, Giancamilli F, Vitale J, Borghi S, et al. COVID-19 outbreak and physical activity in the Italian population: a cross-sectional analysis of the underlying psychosocial mechanisms. Front Psychol. 2020;11: 2100. doi: 10.3389/fpsyg.2020.02100 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Liu Y, Ning Z, Chen Y, Guo M, Liu Y, Gali NK, et al. Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals. Nature. 2020;582(7813): 557–560. doi: 10.1038/s41586-020-2271-3 [DOI] [PubMed] [Google Scholar]
  • 6.Klompas M, Baker MA, Rhee C. Airborne transmission of SARS-CoV-2: Theoretical considerations and available evidence. JAMA. doi: 10.1001/jama.2020.12458 [DOI] [PubMed] [Google Scholar]
  • 7.Noorimotlagh Z, Jaafarzadeh N, Martínez SS, Mirzaee SA. A systematic review of possible airborne transmission of the COVID-19 virus (SARS-CoV-2) in the indoor air environment. Environ Res. 2021;193: 110612. doi: 10.1016/j.envres.2020.110612 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Johnson GR, Morawska L. The mechanism of breath aerosol formation. J Aerosol Med Pulm Drug Deliv. 2009;22(3): 229–237. doi: 10.1089/jamp.2008.0720 [DOI] [PubMed] [Google Scholar]
  • 9.Mangram AJ, Horan TC, Pearson ML, et al. Guideline for prevention of surgical site infection, 1999. Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee. Am J Infect Control. 1999;27: 97–132; quiz 133–4; discussion 196. [PubMed] [Google Scholar]
  • 10.Chauveaux D. Preventing surgical-site infections: measures other than antibiotics. Orthop Traumatol Surg Res. 2015;101(1 Suppl): S77–S83. doi: 10.1016/j.otsr.2014.07.028 [DOI] [PubMed] [Google Scholar]
  • 11.Seki Y, Nakashima D, Shiraishi Y, Ryuzaki T, Ikura H, Miura K, et al. A novel device for detecting anaerobic threshold using sweat lactate during exercise. Sci Rep. 2021;11(1): 4929. doi: 10.1038/s41598-021-84381-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Schnohr P, O’Keefe JH, Marott JL, Lange P, Jensen GB. Dose of jogging and long-term mortality: the Copenhagen City Heart Study. J Am Coll Cardiol. 2015;65(5): 411–419. doi: 10.1016/j.jacc.2014.11.023 [DOI] [PubMed] [Google Scholar]
  • 13.Wen CP, Wai JP, Tsai MK, Yang YC, Cheng TY, Lee MC, et al. Minimum amount of physical activity for reduced mortality and extended life expectancy: a prospective cohort study. Lancet. 2011;378(9798): 1244–1253. doi: 10.1016/S0140-6736(11)60749-6 [DOI] [PubMed] [Google Scholar]
  • 14.Lee IM, Shiroma EJ, Lobelo F, Puska P, Blair SN, Katzmarzyk PT, et al. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. Lancet. 2012;380(9838): 219–229. doi: 10.1016/S0140-6736(12)61031-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Zhao M, Veeranki SP, Magnussen CG, Xi B. Recommended physical activity and all cause and cause specific mortality in US adults: prospective cohort study. BMJ. 2020;370: m2031. doi: 10.1136/bmj.m2031 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Strain T, Wijndaele K, Dempsey PC, Sharp SJ, Pearce M, Jeon J, et al. Wearable-device-measured physical activity and future health risk. Nat Med. 2020;26(9): 1385–1391. doi: 10.1038/s41591-020-1012-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11): e596–e646. doi: 10.1161/CIR.0000000000000678 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Meyer J, McDowell C, Lansing J, Brower C, Smith L, Tully M, et al. Changes in physical activity and sedentary behavior in response to COVID-19 and their associations with mental health in 3052 US adults. Int J Environ Res Public Health. 2020;17(18): E6469. doi: 10.3390/ijerph17186469 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Sher L. The impact of the COVID-19 pandemic on suicide rates. QJM. 2020;113(10): 707–712. doi: 10.1093/qjmed/hcaa202 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Sassone B, Mandini S, Grazzi G, Mazzoni G, Myers J, Pasanisi G. Impact of COVID-19 pandemic on physical activity in patients with implantable cardioverter-defibrillators. J Cardiopulm Rehabil Prev. 2020;40(5): 285–286. doi: 10.1097/HCR.0000000000000539 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Fluetsch N, Levy C, Tallon L. The relationship of physical activity to mental health: A 2015 behavioral risk factor surveillance system data analysis. J Affect Disord. 2019;253: 96–101. doi: 10.1016/j.jad.2019.04.086 [DOI] [PubMed] [Google Scholar]
  • 22.Chan JF, Yuan S, Kok KH, To KKW, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020;395: 514–523. doi: 10.1016/S0140-6736(20)30154-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Gentil P, de Lira CAB, Souza D, Jimenez A, Mayo X, de Fátima Pinho Lins Gryschek AL, et al. Resistance training safety during and after the SARS-Cov-2 outbreak: Practical recommendations. Biomed Res Int. 2020;2020: 3292916. doi: 10.1155/2020/3292916 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Morawska L, Cao J. Airborne transmission of SARS-CoV-2: The world should face the reality. Environ Int. 2020;139: 105730. doi: 10.1016/j.envint.2020.105730 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Asadi S, Bouvier N, Wexler AS, Ristenpart WD. The coronavirus pandemic and aerosols: Does COVID-19 transmit via expiratory particles. Aerosol Sci Technol. 2020;0(0): 1–4. doi: 10.1080/02786826.2020.1749229 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med. 2020;382(16): 1564–1567. doi: 10.1056/NEJMc2004973 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review. JAMA. 2020;324(8): 782–793. doi: 10.1001/jama.2020.12839 [DOI] [PubMed] [Google Scholar]
  • 28.Leung NHL, Chu DKW, Shiu EYC, Chan KH, McDevitt JJ, Hau BJP, et al. Author Correction: Respiratory virus shedding in exhaled breath and efficacy of face masks. Nat Med. 2020;26(6): 981. doi: 10.1038/s41591-020-0946-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Anderson EL, Turnham P, Griffin JR, Clarke CC. Consideration of the aerosol transmission for COVID-19 and public health. Risk Anal. 2020;40(5): 902–907. doi: 10.1111/risa.13500 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Pires FO, Noakes TD, Lima-Silva AE, Bertuzzi R, Ugrinowitsch C, Lira FS, et al. Cardiopulmonary, blood metabolite and rating of perceived exertion responses to constant exercises performed at different intensities until exhaustion. Br J Sports Med. 2011;45(14): 1119–1125. doi: 10.1136/bjsm.2010.079087 [DOI] [PubMed] [Google Scholar]
  • 31.Baron B, Noakes TD, Dekerle J, Moullan F, Robin S, Matran R, et al. Why does exercise terminate at the maximal lactate steady state intensity. Br J Sports Med. 2008;42(10): 828–833. doi: 10.1136/bjsm.2007.040444 [DOI] [PubMed] [Google Scholar]
  • 32.Hopker JG, O’Grady C, Pageaux B. Prolonged constant load cycling exercise is associated with reduced gross efficiency and increased muscle oxygen uptake. Scand J Med Sci Sports. 2017;27(4): 408–417. doi: 10.1111/sms.12673 [DOI] [PubMed] [Google Scholar]
  • 33.Mattioli AV, Sciomer S, Cocchi C, Maffei S, Gallina S. Quarantine during COVID-19 outbreak: Changes in diet and physical activity increase the risk of cardiovascular disease. Nutr Metab Cardiovasc Dis. 2020;30(9): 1409–1417. doi: 10.1016/j.numecd.2020.05.020 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Davor Plavec

7 Jul 2021

PONE-D-21-09706

Laminar flow ventilation system to prevent airborne infection during exercise in the COVID-19 crisis: a single-center observational study

PLOS ONE

Dear Dr. KATSUMATA,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please make corrections as suggested by reviewer.

Please submit your revised manuscript by Aug 21 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Davor Plavec, MD, MSc, PhD, Prof.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. In your Methods section, please provide additional information about the participant recruitment method and the demographic details of your participants. Please ensure you have provided sufficient details to replicate the analyses such as: a) the recruitment date range (month and year), b) a description of any inclusion/exclusion criteria that were applied to participant recruitment, c) a statement as to whether your sample can be considered representative of a larger population, d) a description of how participants were recruited."

3. During the internal evaluation of the manuscript we have noted in the Methods section that one patient experienced a subdural hematoma. Please provide further clarification regarding whether this was a direct result of the exercise intervention. Please provide details regarding any treatment which the participant received.

4. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified: 1) whether the ethics committee approved the verbal/oral consent procedure, 2) why written consent could not be obtained, and 3) how verbal/oral consent was recorded. If your study included minors, please state whether you obtained consent from parents or guardians in these cases. If the need for consent was waived by the ethics committee, please include this information.

5. Thank you for providing the following Funding Statement: 

"Yoshinori Katsumata has a financial relationship with Kimura Memorial Heart Foundation Research Grant for 2019, Suzuken Memorial Foundation, Foundation for Total Health Promotion, and Research Grant for Public Health Science. Eiji Kobayashi has a financial relationship with Nippon Medical & Chemical Instruments Co. Ltd. Motoaki Sano, Hiroki Okawara, Tomonori Sawada, Genki Ichihara, and Kazuki Sato declare that they have no competing interests."

We note that one or more of the authors is affiliated with the funding organization, indicating the funder may have had some role in the design, data collection, analysis or preparation of your manuscript for publication; in other words, the funder played an indirect role through the participation of the co-authors.

If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors' salaries and/or research materials, please review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study in the Author Contributions section of the online submission form. Please make any necessary amendments directly within this section of the online submission form.  Please also update your Funding Statement to include the following statement: “The funder provided support in the form of salaries for authors [insert relevant initials], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.”

If the funding organization did have an additional role, please state and explain that role within your Funding Statement.

Please also provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc. 

Within your Competing Interests Statement, please confirm that this commercial affiliation does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: "This does not alter our adherence to  PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests). If this adherence statement is not accurate and  there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

6. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

"Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

7. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section.

8. We note that Figure 1 in your submission contain copyrighted images. All PLOS content is published under the Creative Commons Attribution License (CC BY 4.0), which means that the manuscript, images, and Supporting Information files will be freely available online, and any third party is permitted to access, download, copy, distribute, and use these materials in any way, even commercially, with proper attribution. For more information, see our copyright guidelines: http://journals.plos.org/plosone/s/licenses-and-copyright.

We require you to either (1) present written permission from the copyright holder to publish these figures specifically under the CC BY 4.0 license, or (2) remove the figures from your submission:

1. You may seek permission from the original copyright holder of Figure 1 to publish the content specifically under the CC BY 4.0 license.

We recommend that you contact the original copyright holder with the Content Permission Form (http://journals.plos.org/plosone/s/file?id=7c09/content-permission-form.pdf) and the following text: “I request permission for the open-access journal PLOS ONE to publish XXX under the Creative Commons Attribution License (CCAL) CC BY 4.0 (http://creativecommons.org/licenses/by/4.0/). Please be aware that this license allows unrestricted use and distribution, even commercially, by third parties. Please reply and provide explicit written permission to publish XXX under a CC BY license and complete the attached form.”

Please upload the completed Content Permission Form or other proof of granted permissions as an "Other" file with your submission. In the figure caption of the copyrighted figure, please include the following text: “Reprinted from [ref] under a CC BY license, with permission from [name of publisher], original copyright [original copyright year].”

2. If you are unable to obtain permission from the original copyright holder to publish these figures under the CC BY 4.0 license or if the copyright holder’s requirements are incompatible with the CC BY 4.0 license, please either i) remove the figure or ii) supply a replacement figure that complies with the CC BY 4.0 license. Please check copyright information on all replacement figures and update the figure caption with source information. If applicable, please specify in the figure caption text when a figure is similar but not identical to the original image and is therefore for illustrative purposes only.

9. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: I think it is a very valuable paper especially in regard to present situation. Though I would be very happy if you could perform Power analysis (then you do not have to say in limitations that you have a small sample)

Also regarding the language. Do not use WE did this, WE did that. Please use impersonal, passive voice.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Nov 10;16(11):e0257549. doi: 10.1371/journal.pone.0257549.r002

Author response to Decision Letter 0


2 Aug 2021

To Reviewer #1

#1. I think it is a very valuable paper especially in regard to present situation. Though I would be very happy if you could perform Power analysis (then you do not have to say in limitations that you have a small sample)

Response:

� Thank you very much for pointing this out. As suggested, a power analysis was performed. Based on a pre-performed Shapiro-wilk test, multiple comparisons of changes in the number of airborne particulates involving each incremental exercise period from the warm-up were made using the repeated analysis of variance with the Dunnet test as a post-hoc test. It revealed a significant and gradual increase in the respiratory droplets with time with a large effect size. Also, Cohen’s d was calculated using the value of t for paired t test to compare the droplet concentrations from spray or from the oral cavity during vigorous exercise before and after the activation of LFVS. We revised the related parts of the Materials and Methods, Results, Discussion, and Table, as shown below:

-Method section (Statistical analyses)-

The results are presented as means with standard deviations for continuous variables and as percentages for categorical variables, as appropriate. Based on a pre-performed Shapiro-wilk test, multiple comparisons of changes in the number of airborne particulates involving each incremental exercise period from the warm-up were made using the repeated analysis of variance with the Dunnet test as a post-hoc testSteel test. Student’s paired t-test was used to compare the droplet concentrations from spray or from the oral cavity during vigorous exercise before and after the activation of LFVS. We calculated Cohen’s d using the value of t for paired t test. SPSS, version 25.0 (SPSS Inc., Chicago, Illinois), was used for analysis, and p<0.05 (2-sided) was set to define statistical significance.

-Result section-

Monitoring particulates during exercise

Baseline characteristics of the subjects are summarized in Table 1. The subjects were predominantly male (80%), with an average age of 29 ± 12 years. Figure 3 shows the representative data for the particulates, lactate in sweat, and heart rate during exercise. A steady number of particulates before the LT was followed by a significant and gradual increase in the respiratory droplets after the LT, particularly during anaerobic exercise with a large effect size (Fig. 3 and Table 2).

-Result section-

Effect of the LFVS on the particulates during vigorous exercise

The LFVS was activated during a constant load of exercise intensity above the LT, in which the concentration of particulates in the exhaled air increased. Notably, particulates exhaled during exercise were almost completely removed by the LFVS (>0.3 μm: 2120800±759700 vs. 560 ± 170; p<0.001, p<0.001, n=10; Fig. 4 and Table 3).

-Discussion section-

Limitations

The present study has some limitations. First, as a single-center observational study, there may have been a selection bias. Second, the number of subjects was small. Third, our study did not allow for an examination of the possibility of LFVS in preventing the COVID-19 infection. A further randomized study with a large sample size and long-term follow-up for the prevention of COVID-19 infection is required to overcome these limitations.

#2. Also regarding the language. Do not use WE did this, WE did that. Please use impersonal, passive voice.

Response:

� As you mentioned, we revised the manuscript to remove the use of “We” when not appropriate.

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

Response:

� As suggested, we revised the manuscript in accordance with PLOS ONE's style requirements.

2. In your Methods section, please provide additional information about the participant recruitment method and the demographic details of your participants. Please ensure you have provided sufficient details to replicate the analyses such as: a) the recruitment date range (month and year), b) a description of any inclusion/exclusion criteria that were applied to participant recruitment, c) a statement as to whether your sample can be considered representative of a larger population, d) a description of how participants were recruited."

3. During the internal evaluation of the manuscript we have noted in the Methods section that one patient experienced a subdural hematoma. Please provide further clarification regarding whether this was a direct result of the exercise intervention. Please provide details regarding any treatment which the participant received.

Response:

� As suggested, we have revised the Methods section, as shown below:

-Method Section-

Subjects aged 20-80 years were recruited via a web system in October 2020. Exclusion criteria included receiving medication and having comorbidities, such as hypertension, diabetes, or active lung diseases. Twenty healthy subjects were enrolled recruited in this study The subjects had a broad spectrum of aerobic capacities and fitness levels, including athletes, and had no comorbidities, such as hypertension, diabetes, or active lung diseases. One of them had experienced a subdural hematoma 6 months ago. At the time he participated in this study, he was cured of his disease and was not receiving ongoing treatment. In addition, he was actively engaged in daily exercise. All of them received no medication. They can be considered representative of a larger population. The study protocol was approved by the Institutional Review Board (IRB) of Keio University School of Medicine [permission number; 20190229], and the study was conducted in accordance with the Declaration of Helsinki. Subjects provided verbal informed consent, because the IRB approved use of oral consent in accordance with Japanese guidance for clinical research. Verbal consents were recorded as experimental notes in this study.

4. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified: 1) whether the ethics committee approved the verbal/oral consent procedure, 2) why written consent could not be obtained, and 3) how verbal/oral consent was recorded. If your study included minors, please state whether you obtained consent from parents or guardians in these cases. If the need for consent was waived by the ethics committee, please include this information.

Response:

� Thank you very much for pointing this out. The IRB approved the use of oral consent in accordance with Japanese guidance for clinical research. The verbal consent was recorded as an experimental note in this study. Subjects aged 20-80 years old were recruited. We revised the Methods section, as shown below:

-Method Section-

Subjects aged 20-80 years were recruited via a web system in October 2020. Exclusion criteria included receiving medication and having comorbidities, such as hypertension, diabetes, or active lung diseases. Twenty healthy subjects were enrolled recruited in this study The subjects had a broad spectrum of aerobic capacities and fitness levels, including athletes, and had no comorbidities, such as hypertension, diabetes, or active lung diseases. One of them had experienced a subdural hematoma 6 months ago. At the time he participated in this study, he was cured of his disease and was not receiving ongoing treatment. In addition, he was actively engaged in daily exercise. All of them received no medication. They can be considered representative of a larger population. The study protocol was approved by the Institutional Review Board (IRB) of Keio University School of Medicine [permission number; 20190229], and the study was conducted in accordance with the Declaration of Helsinki. Subjects provided verbal informed consent because the IRB approved use of oral consent in accordance with Japanese guidance for clinical research. Verbal consents were recorded as experimental notes in this study.

5. Thank you for providing the following Funding Statement:

"Yoshinori Katsumata has a financial relationship with Kimura Memorial Heart Foundation Research Grant for 2019, Suzuken Memorial Foundation, Foundation for Total Health Promotion, and Research Grant for Public Health Science. Eiji Kobayashi has a financial relationship with Nippon Medical & Chemical Instruments Co. Ltd. Motoaki Sano, Hiroki Okawara, Tomonori Sawada, Genki Ichihara, and Kazuki Sato declare that they have no competing interests."

We note that one or more of the authors is affiliated with the funding organization, indicating the funder may have had some role in the design, data collection, analysis or preparation of your manuscript for publication; in other words, the funder played an indirect role through the participation of the co-authors.

If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors' salaries and/or research materials, please review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study in the Author Contributions section of the online submission form. Please make any necessary amendments directly within this section of the online submission form. Please also update your Funding Statement to include the following statement: “The funder provided support in the form of salaries for authors [insert relevant initials], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.”

If the funding organization did have an additional role, please state and explain that role within your Funding Statement.

Please also provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc.

Within your Competing Interests Statement, please confirm that this commercial affiliation does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: "This does not alter our adherence to PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests). If this adherence statement is not accurate and there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Response:

� As suggested, we revised the Methods section, as shown below:

Funding Statement

The laminar airflow ventilation system was developed in collaboration with E.K. and Nippon Medical & Chemical Instruments Co. Ltd. This work was partly supported by a Grant-in-Aid from Scientific Research from the Japan Agency for Medical Research and Development [ID. 21ek0210130h0003] and by Kimura Memorial Heart Foundation Research Grant for 2019 [N/A], Suzuken Memorial Foundation [N/A], Foundation for Total Health Promotion [N/A], and Research Grant for Public Health Science [N/A].

The funders provided support in the form of financial supports for authors [Y.K., E.K.], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.

Competing Interests Statement

Yoshinori Katsumata has a financial relationship with Kimura Memorial Heart Foundation Research Grant for 2019, Suzuken Memorial Foundation, Foundation for Total Health Promotion, and Research Grant for Public Health Science. Eiji Kobayashi has a financial relationship with Nippon Medical & Chemical Instruments Co. Ltd. Motoaki Sano, Hiroki Okawara, Tomonori Sawada, Genki Ichihara, and Kazuki Sato declare that they have no competing interests.

This does not alter our adherence to PLOS ONE policies on sharing data and materials.

6. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

"Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

Response:

� As suggested, we uploaded the minimal data set. And, we revised the manuscriot, as shown below:

Availability of data and material

The datasets are within the manuscript and its Supporting Information files.

The datasets generated during and/or analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request.

7. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section.

Response:

� As suggested, we revised the manuscript.

8. We note that Figure 1 in your submission contain copyrighted images. All PLOS content is published under the Creative Commons Attribution License (CC BY 4.0), which means that the manuscript, images, and Supporting Information files will be freely available online, and any third party is permitted to access, download, copy, distribute, and use these materials in any way, even commercially, with proper attribution. For more information, see our copyright guidelines: http://journals.plos.org/plosone/s/licenses-and-copyright.

We require you to either (1) present written permission from the copyright holder to publish these figures specifically under the CC BY 4.0 license, or (2) remove the figures from your submission:

1. You may seek permission from the original copyright holder of Figure 1 to publish the content specifically under the CC BY 4.0 license.

We recommend that you contact the original copyright holder with the Content Permission Form (http://journals.plos.org/plosone/s/file?id=7c09/content-permission-form.pdf) and the following text: “I request permission for the open-access journal PLOS ONE to publish XXX under the Creative Commons Attribution License (CCAL) CC BY 4.0 (http://creativecommons.org/licenses/by/4.0/). Please be aware that this license allows unrestricted use and distribution, even commercially, by third parties. Please reply and provide explicit written permission to publish XXX under a CC BY license and complete the attached form.”

Please upload the completed Content Permission Form or other proof of granted permissions as an "Other" file with your submission. In the figure caption of the copyrighted figure, please include the following text: “Reprinted from [ref] under a CC BY license, with permission from [name of publisher], original copyright [original copyright year].”

2. If you are unable to obtain permission from the original copyright holder to publish these figures under the CC BY 4.0 license or if the copyright holder’s requirements are incompatible with the CC BY 4.0 license, please either i) remove the figure or ii) supply a replacement figure that complies with the CC BY 4.0 license. Please check copyright information on all replacement figures and update the figure caption with source information. If applicable, please specify in the figure caption text when a figure is similar but not identical to the original image and is therefore for illustrative purposes only.

Response:

� As suggested, we completed the Content Permission Form.

9. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Response:

� Thank you. We have not cited papers that have been retracted. No changes were made to the references.

Attachment

Submitted filename: Response_to_Reviewers_laminar.docx

Decision Letter 1

Davor Plavec

6 Sep 2021

Laminar flow ventilation system to prevent airborne infection during exercise in the COVID-19 crisis: a single-center observational study

PONE-D-21-09706R1

Dear Dr. Katsumata,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Davor Plavec, MD, MSc, PhD, Prof.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

After making suggested corrections the manuscript is now acceptable for publication.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Thank you for addressing my remarks regarding impersonal language, power analysis and limitations

.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Acceptance letter

Davor Plavec

19 Oct 2021

PONE-D-21-09706R1

Laminar flow ventilation system to prevent airborne infection during exercise in the COVID-19 crisis: a single-center observational study

Dear Dr. Katsumata:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Davor Plavec

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. Particulates from an ultrasonic humidifier using the laminar airflow ventilation system (LFVS).

    Particulates from an ultrasonic humidifier using the laminar airflow ventilation system (LFVS). The concentration of particulates (>0.3 μm) from an ultrasonic humidifier before and after the activation of the LFVS (n = 10). ##p<0.001 compared with the off LFVS.

    (PDF)

    S1 Movie. The performance of the vertical laminar flow ventilation system using artificial droplets.

    (AVI)

    S1 File. Data set.

    (XLSX)

    Attachment

    Submitted filename: Response_to_Reviewers_laminar.docx

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting information files.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES